NASDAQ:IOBT IO Biotech Q1 2025 Earnings Report $1.02 +0.04 (+4.08%) As of 05/15/2025 04:00 PM Eastern Earnings HistoryForecast IO Biotech EPS ResultsActual EPSN/AConsensus EPS -$0.45Beat/MissN/AOne Year Ago EPSN/AIO Biotech Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AIO Biotech Announcement DetailsQuarterQ1 2025Date5/14/2025TimeBefore Market OpensConference Call DateWednesday, May 14, 2025Conference Call Time8:00AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) IO Biotech Earnings HeadlinesIO Biotech price target raised to $14 from $12 at H.C. WainwrightMay 15 at 10:27 PM | finance.yahoo.comIO Biotech Reports First Quarter 2025 Financial Results and Business HighlightsMay 14 at 8:05 AM | globenewswire.comTrump’s Bitcoin Reserve is No Accident…Big Swings in Crypto Right Now — and Bigger Moves Could Be Coming That kind of whiplash might scare some folks off — but for investors who've been around the block, it's usually a sign that something big is brewing.May 16, 2025 | Crypto 101 Media (Ad)IO Biotech (IOBT) Projected to Post Quarterly Earnings on TuesdayMay 11, 2025 | americanbankingnews.comIO Biotech unveils promising vaccine preclinical dataApril 27, 2025 | investing.comIO Biotech Presents New Preclinical Data Supporting Dual-Antigen and TGF-β-Directed Vaccines for Enhancing Anti-Tumor Immunity at AACR 2025April 27, 2025 | nasdaq.comSee More IO Biotech Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like IO Biotech? Sign up for Earnings360's daily newsletter to receive timely earnings updates on IO Biotech and other key companies, straight to your email. Email Address About IO BiotechIO Biotech (NASDAQ:IOBT), a clinical-stage biopharmaceutical company, develops immune-modulating therapeutic cancer vaccines based on the T-win technology platform. The company's lead product candidate, IO102-IO103, which is designed to target immunosuppressive mechanisms mediated by Indoleamine 2,3-dehydrogenase (IDO), and programmed death-ligand (PD-L1) that is in phase 3 clinical trial to treat melanoma, as well as in phase 2 clinical trial to treat lung, head and neck, bladder, and melanoma cancer. It also develops IO112, a product candidate that contains a single Arginase 1-derived peptide designed to target T cells that recognize epitopes derived from Arginase 1 for the treatment of cancers. The company was incorporated in 2014 and is based in Copenhagen, Denmark.View IO Biotech ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery? Upcoming Earnings PDD (5/20/2025)Palo Alto Networks (5/20/2025)Synopsys (5/20/2025)Home Depot (5/20/2025)Mitsubishi UFJ Financial Group (5/21/2025)Sumitomo Mitsui Financial Group (5/21/2025)Medtronic (5/21/2025)TJX Companies (5/21/2025)Snowflake (5/21/2025)Lowe's Companies (5/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
